
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Docetaxel (Taxotere) has been approved by the FDA for the treatment of hormone-refractory metastatic prostate cancer when used in combination with prednisone.





